Biobanking for epidemiological research and public health

Pathobiology

Volumn 74, Issue 4, 2007, Pages 227-238

  Brand, Angela M ^a,c   Probst Hensch, Nicole M ^b  

^a German Center for Public Health Genomics   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c BIELEFELD UNIVERSITY OF APPLIED SCIENCES   (Germany)

Author keywords

Biobanking; Epidemiological research; Genomics; Health policy development; Health services; Individual health information management; Public health; Surveillance systems

Indexed keywords

EPIDEMIOLOGICAL DATA; GENOME ANALYSIS; GENOTYPE; HEALTH CARE FACILITY; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HISTOLOGY; HUMAN; MEDICAL ETHICS; MOLECULAR BIOLOGY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PUBLIC HEALTH; REVIEW;

COOPERATIVE BEHAVIOR; EPIDEMIOLOGIC STUDIES; EPIDEMIOLOGY, MOLECULAR; GENETIC PREDISPOSITION TO DISEASE; GENETICS, POPULATION; GENOMICS; HUMANS; POPULATION SURVEILLANCE; PUBLIC HEALTH; TISSUE BANKS;

EID: 34548082017     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000104450     Document Type: Review

References (74)

1. Peltonen L, McKusick VA: Genomics and medicine. Dissecting human disease in the postgenomic era. Science 2001;291:1224-1229.
2. Khoury MJ: Relationship between medical genetics and public health: changing the paradigm of disease prevention and the definition of a genetic disease. Am J Med Gen 1997;17:289-291.
3. Baird PA: Identification of genetic susceptibility to common diseases: the case for regulation. Perspect Biol Med 2000;45:516-528.
4. Lai E, Bansal A, Hughes A: Medical applications of haplotype-based SNP maps: learning to walk before we run. Nat Gen 2002;32:353.
5. Gibbs RA, Belmont JW, Hardenbol P: The International HapMap Project. Nature 2003;426:789-796.
6. Probst-Hensch NM, Ingles SA, Diep AT, Haile RW, Stanczyk FZ, Kolonel LN, Henderson BE: Aromatase and breast cancer susceptibility. Endocr Relat Cancer 1999;6:165-173.
7. Guttmacher AE, Collins FS: Genomic medicine - a primer. N Engl J Med 2002;347:1512-1521.
8. Antonovsky A: Unraveling the Mystery of Health. How People Manage Stress and Stay Well. San Francisco, Bass, 1987.
9. Sing CF, Stengard JH, Kardia SL: Genes, environment, and cardiovascular disease. Arterioscler Thromb Vasc Biol 2003;23:1950.
10. Dorman JS, Mattison DR: Epidemiology, molecular biology and public health; in Khoury MJ, Burke W, Thomson EJ (eds): Genetics and Public Health in the 21st Century. Using Genetic Information to Improve Health and Prevent Disease. New York, Oxford University Press, 2000, pp 103-121.
11. Little J: Reporting and review of the human genome epidemiology studies; in Khoury MJ, Little J, Burke W (eds): Human Genome Epidemiology. A Scientific Foundation for Using Genetic Information to Improve Health and Prevent Disease. New York, Oxford University Press, 2004, pp 168-192.
12. Brand A, Brand H: Public health genetics - challenging 'public health at the crossroads'. Ital J Publ Health 2005;2:59.
13. Lehmann DJ, Cortina-Borja M, Warden DR, Smith D, Sleegens K, Prince JA, van Duijn CM, Kehoe PG: Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer's disease. Am J Epidemiol 2005;162:305-317.
14. Sookoian SC, Gonzalez C, Pirola CJ: Meta-analysis on the G-308A tumor necrosis factor alpha gene variant and phenotypes associated with the metabolic syndrome. Obes Res 2005;13:2122-2131.
15. Gao J, Shan G, Sun B, Thompson PJ, Gao X: Association between polymorphism of tumour necrosis factor alpha-308 gene promoter and astma: a meta-analysis. Thorax 2006;61:466-471.
16. Rothman N, Skibola CF, Wang SS, Morgan G, Lan Q, Smith MT, Spinelli JJ, Willett E, De Sanjose S, Cocco P, Berndt SI, Brennan P, Brooks-Wilson A, Wacholder S, Becker N, Hartge P, Zheng T, Roman E, Holly EA, Boffetta P, Armstrong B, Cozen W, Linet M, Bosch FX, Ennas MG, Holford TR, Gallagher RP, Rollinson S, Bracci PM, Cerhan JR, Whitby D, Moore PS, Leaderer B, Lai A, Spink C, Davis S, Bosch R, Scarpa A, Zhang Y, Severson RK, Yeager M, Chanock S, Nieters A: Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 2006;7:27-38.
17. Collins FS, Patrinos A, Jordan E, Chakravarti A, Gesteland R, Walters L: New Goals for the U.S. Genome Project: 1998-2003. Science 1998;282:682-689.
18. Childs B, Valle D: Genetics, biology and disease. Annu Rev Genomics Hum Genet 2000;1:1-19.
19. Collins FS, McKusick VA: Implications of the Human Genome Project for medical science. JAMA 2001;285:540-544.
20. Burke W: Genomics as a probe for disease biology. N Engl J Med 2003;349:969-974.
21. Ellsworth DL, O'Donnell CJ: Emerging genomic technologies and analytic methods for population- and clinic-based research;in Khoury MJ, Little J, Burke W (eds): Human Genome Epidemiology. A Scientific Foundation for Using Genetic Information to Improve Health and Prevent Disease. New York, Oxford University Press, 2004, pp 17-37.
22. Khoury MJ: From genes to public health: the applications of genetic technology in disease prevention. Genetics Working Group. Am J Public Health 1996;86:1717-1722.
23. Brand A: Prädiktive Gentests - Paradigmenwechsel für Prävention und Gesundheitsversorgung? Gesundheitswesen 2002;64:224-229.
24. French ME, Moore JB: Harnessing Genetics to Prevent Disease and Promote Health. Washington, Partnership for Prevention, 2003.
25. Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Köchli OR, Mross F, Dieterich H, Moch H, Mihatsch M, Kallioniemi OP, Sauter G: Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 2001;159:2249-2256.
26. Hoos A, Urist MJ, Stojadinovic A, Mastorides S, Dudas ME, Leung DHY, Kuo D, Brennan MF, Lewis JJ, Cordon-Cardo C: Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroplastic tumors. Am J Pathol 2001;158:1245-1251.
27. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847.
28. Yoon PW: Public health impact of genetic tests at the end of the 20th century. Genet Med 2001;3:405-410.
29. ARIC Investigators: The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol 1989;129:687-702.
30. Wright AF, Carothers AD, Campbell H: Gene-environment interactions - the BioBank UK study. Pharmacogenomics J 2002;2:75-82.
31. Hakonarson H, Gulcher JR, Stefansson K: deCODE genetics, Inc. Pharmacogenomics 2003;4:209-215.
32. Khoury MJ, Millikan R, Little J, Gwinn M: The emergence of epidemiology in the genomics age. Int J Epidemiol 2004;33:936-944.
33. Khoury MJ, Little J, Burke W: Human genome epidemiology: scope and strategies;in Khoury MJ, Little J, Burke W (eds): Human Genome Epidemiology. New York, Oxford University Press, 2004, pp 3-16.
34. Eylenbosch WJ, Noah ND: Historical aspects; in Eylenbosch WJ, Noah ND (eds): Surveillance in Health and Disease. Oxford, Oxford University Press, 1988, pp 3-8.
35. Langmuir AD: The surveillance of communicable diseases of national importance. N Engl J Med 1963;268:182-192.
36. Brand A, Dabrock P, Paul N, Schröder P: Gesundheitssicherung im Zeitalter der Genomforschung - Diskussion, Aktivitäten und Institutionalisierung von Public Health Genetics in Deutschland. Gutachten zur Bio- und Gentechnologie. Berlin, Friedrich-Ebert-Stiftung, 2004.
37. Khoury MJ, Burke W, Thomson E: Genetics in public health: a framework for the integration of human genetics into public health practice; in Khoury MJ, Burke W, Thomson EJ (eds): Genetics and Public Health in the 21st Century. Using Genetic Information to Improve Health and Prevent Disease. New York, Oxford University Press, 2000, pp 3-23.
38. Zimmern R, Cook C: Genetics and Health. Policy Issues for Genetic Science and Their Implications for Health and Health Services. The Nuffield Trust Genetics Scenario Project. London, Nuffield Trust, 2000.
39. Omenn GS: Public health genetics: an emerging interdisciplinary field for the post-genomic era. Annu Rev Public Health 2000;21:1-13.
40. Walt G: Health Policy: An Introduction to Process and Power. London, Zed Books, 1994.
41. Williams G: Bioethics and large-scale biobanking: individualistic ethics and collective projects. Genomics, Soc Policy 2005;1:50-66.
42. Schröder P: Public Health Ethik in Abgrenzung zur Medizinethik. Bundesgesundheitsblatt 2007;50:103-111.
43. Schröder P: Gendiagnostische Gerechtigkeit. Eine ethische Studie über die Herausforderungen postnataler genetischer Prädiktion. Münster, LIT, 2004.
44. Sass HM: A 'contract model' for genetic research and health care for individuals and families. Eubios J Asian Internat Bioethics 2001;11:130-132.
45. Knoppers BM: Of genomics and public health: building public 'goods'? CMAJ 2005;173:1185-1186.
46. Coughlin S: Ethical issues in epidemiologic research and public health practice. Emerg Themes Epidemiol 2006;3: 16 (http://www.ete-online.com/content/ 3/1/16).
47. Michigan Center for Genomics & Public Health. Ethical, legal and social issues in public health genetics (PHELSI), 2004. http://www.sph.umich. edu/genomics/media/ subpage_autogen/PHELSI.pdf.
48. Beskow LM, Khoury MJ, Baker TG, Thrasher JF: The integration of genomics into public health research, policy and practice in the United States. Community Genet 2001;4:2-11.
49. Frankish CJ, Kwan B, Ratner PA, Higgins JW, Larsen C: Challenges of citizen participation in regional health authorities. Soc Sci Med 2002;54:1471-1480.
50. O'Neill O: Autonomy and Trust in Bioethics. Cambridge, Cambridge University Press, 2002.
51. Geier M, Schröder P: The concept of human dignity in biomedical law;in Sándor J, den Exter AP (eds): Frontiers of European Health Law: A Multidisciplinary Approach. Delft, Erasmus University Press-DocVision, 2003, pp 146-182.
52. Tauber AI: Sick autonomy. Perspect Biol Med 2003;46:484-495.
53. UNESCO. International Declaration on Human Genetic Data. Paris, UNESCO, 2003.
54. Hansen L, Gutteling JM, Lagerwerf L, Bartels J, Roeterdink W: In the Margins of the Public Debate on 'Food and Genes': Research under Commission of the Committee Biotechnology and Food. Enschede, Twente University, 2001.
55. Gutteling J, Hanssen L, van der Veer N, Seydel E: Trust in governance and acceptance of genetically modified food in The Netherlands. Publ Understand Sci 2006;15:103-112.
56. Coulter A, Jenkinson C: European patients' views on the responsiveness of health systems and healthcare providers. Eur J Public Health 2005;15:355-360.
57. Kettis-Lindblad A, Ring L, Viberth E, Hansson MG: Genetic research and donation of tissue samples to biobanks. What do potential sample donors in the Swedish general public think? Eur J Public Health 2005;16:433-440.
58. Erikson JM, Kivnick HQ: Vital Involvement in Old Ages. New York, Norton, 1986.
59. Seigel D: Clinical trials, epidemiology, and public confidence. Stat Med 2003;22:19-25.
60. Gostin LO: Health information: reconciling personal privacy with the public good of human health. Health Care Anal 2001;9:321-335.
61. Bosch X: Group ponders genomics and public health. JAMA 2006;295:1762.
62. Annas GJ: Rules for research on human genetic variation - lessons from Iceland. N Engl J Med 2000;342:1830-1833.
63. Banta HD, Luce BR: Health Care Technology and its Assessment. An International Perspective. New York, Oxford University Press, 1993.
64. Pollitt RJ, Green A, McCabe CJ, Booth A, Cooper NJ, Leonard JV, Nicholl P, Tunaley JR, Virdi NK: Neonatal screening for inborn errors of metabolism: cost, yield and outcome. Health Technol Assess 1997;1:i-iv, 1-202.
65. Brand A: Health Technology Assessment als Basis einer Prioritätensetzung;in Fozouni B, Güntert B (eds): Prioritä tensetzung im deutschen Gesundheitswesen. Berlin, Logos, 2002, pp 158-163.
66. Moldrup C: Medical technology assessment of the ethical, social, and legal implications of pharmacogenomics. A research proposal for an internet citizen jury. Int J Technol Assess Health Care 2002;18:728-732.
67. Perleth M: Evidenzbasierte Entscheidungs-unterstützung im Gesundheitswesen. Konzepte und Methoden der systematischen Bewertung medizinischer Technologien (Health Technology Assessment) in Deutschland. Berlin, Verlag für Wissenschaft und Kultur, 2003.
68. AETMIS (Agence d́valuation des technologies et des modes d'intervention en santé). Health technology assessment in genetics and policy-making in Canada: towards a sustainable development. Montreal, AETMIS Symposium, September 11-12th, 2003.
69. Shani S, Siebzehner MI, Luxenburg O, Shemer J: Setting priorities for the adoption of health technologies on a national level - the Israeli experience. Health Policy 2000;54:169-185.
70. Gwinn M, Khoury MJ: Genomics and public health in the United States: signposts on the translation highway. Community Genet 2006;9:21-26.
71. Smith GD, Ebrahim S, Lewis S, Hansell AL, Palmer L, Burton PR: Genetic epidemiology and public health: hope, hype, and future prospects. Lancet 2005;366:1484-1498.
72. Daar AS: Top 10 biotechnologies for improving health in developing countries. Nat Genet 2002;32:229-232.
73. Brand A: Public health and genetics - dangerous combination? View-point section. Eur J Publ Health 2005;15:113-116.
74. Schulte in den Bäumen T: Governance in genomics. Ital J Public Health 2006;4:46-52.